As of the latest Form 4 filed Jul 9, 2026.
What ATAI Life Sciences BV insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 17 most recent filings for ATAI.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-09 | 2026-07-07 | HERSHBERG ROBERT Director | SSale | −100K | $4.96 | $496K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | HERSHBERG ROBERT, Director | MExercise | +51.1K | $1.35 | $69.0K | Yes (planned) | Form 4 ↗ |
| 2026-07-09 | 2026-07-07 | HERSHBERG ROBERT, Director | MExercise | +48.9K | $1.35 | $66.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-26 | Kochendoerfer Gerd Chief Operating Officer | SSale | −50.0K | $5.00 | $250K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-26 | Kochendoerfer Gerd, Chief Operating Officer | MExercise | +50.0K | $1.60 | $80.0K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Craig Kevin James Chief Medical Officer | SSale | −42.6K | $4.51 | $192K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Craig Kevin James, Chief Medical Officer | MExercise | +9.53K | $1.18 | $11.2K | Yes (planned) | Form 4 ↗ |
| 2026-06-29 | 2026-06-25 | Craig Kevin James, Chief Medical Officer | MExercise | +33.1K | $1.50 | $49.6K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Craig Kevin James Chief Medical Officer | SSale | −42.6K | $5.00 | $213K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Craig Kevin James, Chief Medical Officer | MExercise | +15.3K | $1.84 | $28.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Craig Kevin James, Chief Medical Officer | MExercise | +27.3K | $1.50 | $40.9K | Yes (planned) | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Angermayer Christian Director | MExercise | +103K | $1.34 | $138K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Angermayer Christian, Director | MExercise | +410K | $1.64 | $673K | No | Form 4 ↗ |
| 2026-04-10 | 2026-04-08 | Angermayer Christian, Director | MExercise | +46.1K | $1.88 | $86.6K | No | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Craig Kevin James Chief Medical Officer | SSale | −100K | $3.55 | $355K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Craig Kevin James, Chief Medical Officer | MExercise | +23.8K | $1.50 | $35.7K | Yes (planned) | Form 4 ↗ |
| 2026-03-24 | 2026-03-20 | Craig Kevin James, Chief Medical Officer | MExercise | +76.2K | $1.18 | $89.9K | Yes (planned) | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also ATAI’s full analysis or the market-wide insider trading feed. The tabs above jump to ATAI’s other SEC data.
Source: SEC Form 4 filings for ATAI, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.